Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.41 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.48 |
| ▸ | C1S | P09871 | 3/20 | 0.48 |
| ▸ | TPMT | P51580 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 4/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10168066 | 0.97 | LMNA (0.54) | LMNAPRSS1PRSS3PRSS2C1S | |
| SCHEMBL17306879 | 0.81 | C1S (0.50) | LMNAPRSS1PRSS3PRSS2C1S | |
| SCHEMBL3335604 | 0.81 | LMNA (0.45) | LMNAPRSS1PRSS3PRSS2C1S | |
| Hydrochloric Acid SCHEMBL1436037 | 0.77 | PRSS1 (0.61) | LMNAPRSS1PRSS3PRSS2C1S | |
| SCHEMBL13948235 | 0.76 | PRSS1 (0.63) | LMNAPRSS1PRSS3PRSS2C1S | |
| Hydrochloric Acid SCHEMBL8828788 | 0.75 | LMNA (0.48) | LMNAPRSS1PRSS3PRSS2C1S | |
| Hydrochloric Acid SCHEMBL14486940 | 0.75 | HCAR2 (0.53) | LMNAPRSS1PRSS3PRSS2C1S | |
| SCHEMBL12857372 | 0.74 | MEN1 (0.51) | LMNAPRSS1PRSS3PRSS2F2 | |
| Hydrochloric Acid SCHEMBL1033555 | 0.74 | LMNA (1.00) | LMNAPRSS1PRSS3PRSS2C1S | |
| Hydrochloric Acid SCHEMBL4371939 | 0.74 | PARP1 (0.58) | LMNATPMTBLMRECQLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001850-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | AHAMMUNE BIOSCIENCES PRIVATE LTD (IN) | 2026-01-01 | — | — | US | disclosed |
| US-12378203-B2 | Imidazole compounds, process for the synthesis and uses thereof | AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) | 2025-08-05 | — | — | US | disclosed |
| US-9508939-B2 | Compound and organic electroluminescent element produced using same | IDEMITSU KOSAN CO., LTD. (JP) | 2016-11-29 | — | — | US | disclosed |
| US-20160172604-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| US-9023852-B2 | 1, 2, 4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | REMYND NV (BE) | 2015-05-05 | — | — | US | disclosed |
| EP-2726470-B1 | 1,2,4-THIADIAZOL-5-YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2015-04-29 | — | — | EP | disclosed |
| US-20140128404-A1 | 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | REMYND NV (BE) | 2014-05-08 | — | — | US | disclosed |
| EP-2726470-A1 | 1, 2, 4 -THIADIAZOL- 5 -YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT NEURODEGENERATIVE DISEASES | reMynd NV (BE) | 2014-05-07 | — | — | EP | disclosed |
| WO-2013004642-A1 | 1, 2, 4 -THIADIAZOL- 5 -YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2013-01-10 | — | — | WO | disclosed |
| EP-1534680-B1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | PHARMACO INVESTMENTS INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20050096348-A1 | DPP IV inhibitors | BOEHRINGER MARKUS (CH) | 2005-05-05 | — | — | US | disclosed |
| US-6861440-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20050004122-A1 | Prenylation inhibitors containing dimethylcyclobutane and methods of their synthesis and use | DEVELOPMENT PARTNERS, LLC | 2005-01-06 | — | — | US | disclosed |
| EP-1441719-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| US-20040116425-A1 | Prenylation inhibitors and methods of their synthesis and use | X-CHEM, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040110780-A1 | Pyrimidine derivatives useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2004-06-10 | — | — | US | disclosed |
| WO-2004016741-A2 | PRENYLATION INHIBITORS CONTAINING DIMETHYL-CYCLOBUTANE AND METHODS OF THEIR SYNTHESIS AND USE | PPD DISCOVERY, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004016592-A1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | PPD DISCOVERY, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004122-A1 | Prenylation inhibitors containing dimethylcyclobutane and methods of their synthesis and use | RCE1, GGPS1, FNTA | HTR3E 4738/4885HTR3B 4744/4885HTR3A 4844/4885 |
| US-20140128404-A1 | 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | MAPT, PSEN1, PSEN2 | HTR3E 2556/4885HTR3B 1734/4885HTR3A 2349/4885 |
| US-20260001850-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | MALT1, ADRM1, CYP11B1 | HTR3E 765/4885HTR3B 1344/4885HTR3A 1194/4885 |
| US-20160172604-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME | L1CAM, LEF1, EML4 | HTR3E 4854/4885HTR3B 4848/4885HTR3A 4878/4885 |
| US-20040110780-A1 | Pyrimidine derivatives useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, GCKR | HTR3E 1605/4885HTR3B 506/4885HTR3A 1381/4885 |
| US-12378203-B2 | Imidazole compounds, process for the synthesis and uses thereof | IDO1, IDO2, NFATC1 | HTR3E 4089/4885HTR3B 3643/4885HTR3A 4450/4885 |
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | HTR3E 1977/4885HTR3B 1436/4885HTR3A 1717/4885 |
| US-20050096348-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | HTR3E 1549/4885HTR3B 901/4885HTR3A 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.